Pfizer's Upjohn strikes generic Viagra deal with telehealth provider Roman

viagra
Greenstone will exclusively supply generic Viagra to Roman, an all-digital telehealth provider. (Pfizer)

Despite positive signs that Pfizer's Mylan-partnered spinoff of generics business Upjohn could be a win for all parties, uncertainty has clouded the new company's future. Now, at least one thing will be certain: It'll have a buyer for generic Viagra––and an unconventional one at that. 

Greenstone, the U.S. subsidiary of Pfizer's Upjohn, has reached an exclusive supply deal with telehealth provider Roman for access to Pfizer's FDA-approved generic of erectile dysfunction med Viagra (sildenafil citrate). 

Under the agreement, Roman will source the generic exclusively through Greenstone with the drug being manufactured in the same European facilities as branded Viagra at no extra cost to Roman subscribers, Pfizer said in a release. Roman is a subsidiary of telehealth provider Ro specializing in men's health, Pfizer said.

Pfizer's decision to provide generic Viagra exclusively to Roman comes as the drugmaker prepares for its much-ballyhooed Upjohn spinoff with generics giant Mylan. 

RELATED: Pfizer may look messy post-Upjohn spinoff, but better days could be ahead: analyst

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.